⭐️Imaging of the SIJ in psoriatic axSpA is similar to axSpA associated with iritis or colitis! Abst#0902 (https://t.co/f55Vfi1LSS) #ACR21 @RheumNow https://t.co/UCXrwPiyhh

• Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting wi…

Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondylitis, for disease activity, global functioning and severity of depression. #Abs0909 #ACR21 @RheumNow https://t.co/2n6Y5ZB1Ot https://t.co/zIMEzHBUrh

• How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Pa…

Predictors of clinical remission in AS patients Rx with TNFi ⭐️Age and 3-mo BASDAI improvement➡️ predictor of clinical remission criteria ⭐️Normalized ESR and CRP at month 3 were predictors of achievement of BASDAI-CRP Abst#0931 #ACR21 @RheumNow https://t.co/Ot1ypgNg3A

Baseline/ Clinical /Imaging predictors of flare when tapering TNFI in axSpA in remission: ⭐️🔼Baseline physician global VAS 🔼flare in 16 weeks after tapering to 2/3 of standard dose. ⭐️🔼Age 🔼flare within 16 weeks after tapering to 1/2 dose Abst #0929 #ACR21 @RheumNow https://t.co/EFiwKA8z99

AxSpA pts who achieve ASDAS low disease activity (LDA) 6 mo after bDMARD initiation ⭐️ 25% achieved ASDAS LDA ⭐️ASDAS LDA achievers were ♂️ + naïve to c/b DMARDs + with PROM / Clinical improvement ⭐️ASDAS LDA non-achievers=depression, uveitis, IBD Abst# 0925 #ACR21 @RheumNow

Turkish study finds that ETN may be negatively associated w/ the development of ADA in AS pts. Abs 0936 #ACR21 #RheumNow @RheumNow https://t.co/z3pYDpp1NN https://t.co/MR1R41rCHV

• Factors Associated with the Development of Anti-drug Antibodies to Tumour Necro…

Evaluate effectiveness and Rx survival of different TNFI in cohort of axSpA ⭐️No difference among different TNFI ⭐️No difference between nr-axSpA and AS ⭐️Failure to initial TNFI did not diminish effectiveness or drug survival of subsequent TNFi Rx Abst#0938 #ACR21 @RheumNow

Abst0897 #ACR21 @RheumNow radiographic progression in AS accelerates w/age, highest at age 30–39 (mean mSASSS change per year 1.148), followed by 40–49 , 20–29,≥50 & least < 20 (0.643). radiographic damage rapidly ⬆️ among 20s w/risk factors:⬆️ CRP &preexisting syndesmophytes https://t.co/tiAgKUyjJq

SELECT-AXIS 1: UPA 15 mg QD consistently efficacious over 2 years for ASAS40. Low radiographic progression rates in AS pts. No new safety findings were observed. Abs 0924 #ACR21 #RheumNow @RheumNow https://t.co/CWvH1OPGyR https://t.co/uC67fJZDCE

• Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondyli…

SELECT-AXIS 1 Post Hoc Analysis results showed improvement in PROs & reduction in back pain score at 12 weeks predicted clinical outcomes at 1 year in AS pts. Abs 0926 #ACR21 #RheumNow @RheumNow https://t.co/vRVpv1O6YS https://t.co/wjafMf1UPY

• Predictors of 1-Year Treatment Response Among Upadacitinib-Treated Patients wit…

SEC reduced SIJ bone marrow edema in active nr-axSpA pts. Majority of pts both in SEC and PBO arms showed no radiographic progression through 2 years. Abs 0921 #ACR21 #RheumNow @RheumNow https://t.co/yC2AZoacxF https://t.co/pjCL8HCanR

• Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroilia…

Googling rheumatic diseases. On average google search lacked essential information to guide patient decisions. Websites on AS scored the highest on the DISCERN and RA scored the highest on JAMA @RheumNow #ACR21 Abst#0742 https://t.co/k2o2AqYEeh https://t.co/ZKljvA2f4O

• Googling Rheumatic Diseases: Evaluating the Reliability of Information Found on…